It has been reported that Stat3 is a major kinase-independent target of sorafenib in HCC and sorafenib downregulates p-Stat3 and reduces the expression levels of Stat3-related proteins as Mcl-1, survivin, and cyclin D1 by upregulating SHP-1 activity [18–21]. This evidence concerns the gene BIRC5 and hepatocellular carcinoma.